Participation in clinical trials as viewed by the patient:: Understanding cultural and emotional aspects which influence choice

被引:32
作者
Catania, Chiara [1 ,2 ]
De Pas, Tommaso [2 ]
Goldhirsch, Aron [1 ]
Radice, Davide [4 ]
Adamoli, Laura [3 ]
Medici, Marta [3 ]
Verri, Elena [3 ]
Marenghi, Cristina [3 ]
de Braud, Filippo [2 ]
Nole, Franco [3 ]
机构
[1] European Inst Oncol, Div Med Oncol, IT-20141 Milan, Italy
[2] European Inst Oncol, Unit Clin Pharmacol & New Drugs, IT-20141 Milan, Italy
[3] European Inst Oncol, Unit Med Care, IT-20141 Milan, Italy
[4] European Inst Oncol, Div Epidemiol & Biostat, IT-20141 Milan, Italy
关键词
clinical trials; cancer; prejudices; patient information; communication; decision aid;
D O I
10.1159/000151365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients invited to take part in a clinical trial may evoke an archetype on which they may base their decision of adherence to participation, instead of on the study itself. Methods: A 17-item, multiple choice questionnaire was developed, tested and then administered to 102 Italian-speaking patients with advanced lung or breast cancers who had never been exposed to participation in a trial. Results: The questionnaire was answered by all patients. Eighty-five percent were positive about trial participation. Demographic factors did not influence patients' willingness to participate. Trust in the investigator (76%) or in the institute (64%) and hope of receiving a new chance for cure (78%) were cited as reasons to accept participation. A minority was concerned by potential conflicts of interest (31%) or the thought of being 'guinea pigs' (36%), and feared that doctors were interested in advancing their own research, even though there were more efficient drugs available (28%). Fifty percent feared receiving a little-known medicine, and 76% considered that a thorough explanation of toxicity/safety of the proposed treatment helped them decide. Conclusion: Several prejudices, fears and some hopes have been captured by the questionnaire. Understanding such specifics will improve patient information leading patients to a more conscious motivation in deciding whether to participate in a clinical trial. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:177 / 187
页数:11
相关论文
共 25 条
  • [1] ASPINWALL LG, 1999, J NATL CANC I MONOGR, V25, P88
  • [2] Sample size requirements for testing and estimating coefficient alpha
    Bonett, DG
    [J]. JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS, 2002, 27 (04) : 335 - 340
  • [3] Bruera E, 1991, J Palliat Care, V7, P6
  • [4] Public attitudes toward participation in cancer clinical trials
    Comis, RL
    Miller, JD
    Aldigé, CR
    Krebs, L
    Stoval, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 830 - 835
  • [5] Randomized clinical trials in oncology: Understanding and attitudes predict willingness to participate
    Ellis, PM
    Butow, PN
    Tattersall, MHN
    Dunn, SM
    Houssami, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) : 3554 - 3561
  • [6] STATISTICAL-INFERENCE FOR COEFFICIENT-ALPHA
    FELDT, LS
    WOODRUFF, DJ
    SALIH, FA
    [J]. APPLIED PSYCHOLOGICAL MEASUREMENT, 1987, 11 (01) : 93 - 103
  • [7] FRIEDMAN MA, 1990, CANCER, V65, P2376, DOI 10.1002/1097-0142(19900515)65:10+<2376::AID-CNCR2820651504>3.0.CO
  • [8] 2-A
  • [9] Gerrard Meg, 1999, Journal of the National Cancer Institute Monographs, P94
  • [10] Clinical trial accrual among new cancer patients at a community-based cancer center - A prospective study
    Go, RS
    Frisby, KA
    Lee, JA
    Mathiason, MA
    Meyer, CM
    Ostern, JL
    Walther, SM
    Schroeder, JE
    Meyer, LA
    Umberger, KE
    [J]. CANCER, 2006, 106 (02) : 426 - 433